KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Asset Writedowns and Impairment (2020 - 2025)

Historic Asset Writedowns and Impairment for Biogen (BIIB) over the last 9 years, with Q4 2025 value amounting to $39.0 million.

  • Biogen's Asset Writedowns and Impairment rose 1746.99% to $39.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $49.8 million, marking a year-over-year decrease of 3844.25%. This contributed to the annual value of $52.9 million for FY2025, which is 4808.64% down from last year.
  • Latest data reveals that Biogen reported Asset Writedowns and Impairment of $39.0 million as of Q4 2025, which was up 1746.99% from $3.5 million recorded in Q2 2025.
  • In the past 5 years, Biogen's Asset Writedowns and Impairment registered a high of $541.6 million during Q2 2021, and its lowest value of $3.5 million during Q2 2025.
  • For the 5-year period, Biogen's Asset Writedowns and Impairment averaged around $74.7 million, with its median value being $25.8 million (2022).
  • The largest annual percentage gain for Biogen's Asset Writedowns and Impairment in the last 5 years was 53544.02% (2022), contrasted with its biggest fall of 9555.02% (2022).
  • Over the past 5 years, Biogen's Asset Writedowns and Impairment (Quarter) stood at $43.4 million in 2021, then plummeted by 66.36% to $14.6 million in 2022, then soared by 326.71% to $62.3 million in 2023, then tumbled by 46.71% to $33.2 million in 2024, then increased by 17.47% to $39.0 million in 2025.
  • Its Asset Writedowns and Impairment stands at $39.0 million for Q4 2025, versus $3.5 million for Q2 2025 and $7.3 million for Q1 2025.